Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
aTyr PharmaATYR -0.04%14 3-Year EBITDA Growth Rate is 19.60% as of Mar. 2026, which is 19% below its 10-year median of 24.15. GuruFocus rates ATYR with a GF Score™ of 14/100 and a GF Value™ of $0.45 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,136 Biotechnology companies, aTyr Pharma ranks better than 55.81% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 19.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 15.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 36.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of aTyr Pharma was 60.10% per year. The lowest was -8.80% per year. And the median was 24.15% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
aTyr Pharma 3-Year EBITDA Growth Rate Related Terms
ATYR vs IBO, BYSI, MCRB: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, aTyr Pharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
aTyr Pharma 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, aTyr Pharma's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where aTyr Pharma's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 19.60% mean?
aTyr Pharma (ATYR) has a 3-Year EBITDA Growth Rate of 19.60% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for aTyr Pharma and its competitors. This is 19% below median its historical median of 24.15. According to the industry distribution chart, aTyr Pharma ranks #502 out of 1136 companies in the Biotechnology industry, placing it in the top 44.2%.
Is aTyr Pharma's 3-Year EBITDA Growth Rate too high?
aTyr Pharma's current 3-Year EBITDA Growth Rate of 19.60% is 19% below median its 10-year median of 24.15. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. aTyr Pharma's value of 19.60% is 32% above this industry median. Based on the distribution chart, aTyr Pharma ranks #502 out of 1136 companies in the Biotechnology industry, which is above the industry midpoint. Overall, aTyr Pharma has a GF Score™ of 14/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does aTyr Pharma's 3-Year EBITDA Growth Rate compare to IBO and BYSI?
According to the Biotechnology industry distribution chart, aTyr Pharma ranks #502 out of 1136 companies for 3-Year EBITDA Growth Rate. This puts aTyr Pharma in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. aTyr Pharma's value of 19.60% is 32% above this benchmark. While the company's 10-year median is 24.15 vs. the industry median of 14.85, aTyr Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. aTyr Pharma's current 3-Year EBITDA Growth Rate of 19.60% is 32% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for aTyr Pharma and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. aTyr Pharma's current 3-Year EBITDA Growth Rate is 19.60%, which is 19% below median its own 10-year median of 24.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is aTyr Pharma stock overvalued right now?
Based on GuruFocus' analysis, aTyr Pharma (ATYR) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.45, compared to a current price of $0.53 — trading 17.8% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 19.60%, which is 19% below median its 10-year median of 24.15 and 32% above the Biotechnology industry median of 14.85. aTyr Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For aTyr Pharma (ATYR), the current 3-Year EBITDA Growth Rate is 19.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is aTyr Pharma (ATYR) Overvalued in 2026?
Based on GuruFocus' analysis, aTyr Pharma stock appears to be overvalued.
The current stock price of $0.53 is trading 17.8% above its estimated GF Value™ of $0.45.
GuruFocus considers aTyr Pharma to be Modestly Overvalued.
Key valuation signals for ATYR:
3-Year EBITDA Growth Rate: 19.60% (19% below median its 10-year median of 24.15)
GF Value™: $0.45 vs. price of $0.53 (17.8% above fair value)
Industry Position: 32% above the Biotechnology median (#502 of 1136)
No single metric tells the full story. See the ATYR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
14GF Score
Get the complete analysis for ATYR
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATYR has been successfully added to your 
